This is in line with post hoc analyses of pivotal trials and meta-analyses that investigated the impact of sidedness on ORR versus survival end points in patients with RAS wild-type mCRC who received anti-EGFR–based treatment.8,20,21 On the basis of such results, an anti-EGFR–based first-line treatment rarely may be offered on an individual basis to patients with right-sided RAS wild-type mCRC, at least whenever tumor response is the primary goal of treatment and particularly when antiangiogenics and/or triplet chemotherapy are contraindicated. This evidence concerns the gene EGFR and neoplasm.